Next-level medicine with ease – powered by moss.

The ability to manufacture biologics effectively and at scale has become a crucial success factor in the pharmaceutical industry – and its importance will only grow. Novel expression strategies can also provide access to previously uncharted biologics, improve crucial drug properties, and deliver not just ‘more’ but a better product in the first place.

Eleva is uniquely positioned in these markets with our proprietary moss-based manufacturing platform, which has the potential to unlock difficult-to-produce biological therapies.

We substantiate this claim by developing a portfolio of therapeutic candidates independently into clinical development and attract partners for de novo projects. Factor H (CPV-104), our recombinant version of human complement Factor H, is expected to enter clinical studies in its lead indication C3 Glomerulopathy (C3G) in H1 2025. Our recombinant version of a-galactosidase aGal (RPV-001) has already delivered promising initial clinical data in Fabry disease.

All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab-to-GMP-scale manufacturing of challenging proteins with refined and optimized product characteristics. We believe, there are many opportunities in our industry, that would benefit from a synergistic expression strategy and platform right from the start and throughout the entire product development roadmap.